Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 197Bevacizumab 162Fluorouracil 155Capecitabine 137Gemcitabine 133Leucovorin 112pembrolizumab 99Cisplatin 93Drug Therapy 89Irinotecan 81Radiotherapy 73sintilimab 70durvalumab 65130-nm albumin-bound paclitaxel 65Paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 59tislelizumab 58Nivolumab 55Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 48Biopsy 46Surgical Procedures, Operative 40Taxes 38Albumin-Bound Paclitaxel 38Immune Checkpoint Inhibitors 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × azeliragon × Gastrointestinal × Clear all
NCT05766748 2024-06-14

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Cantex Pharmaceuticals

Phase 1/2 Recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡